1-9 of 9
Morten Mau-Sørensen
Close
Sort by
Journal Articles

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia

Clinical Trials & Observations
Christine Chen, David Siegel, Martin Gutierrez, Meagan Jacoby, Craig C. Hofmeister, Nashat Gabrail, Rachid Baz, Morten Mau-Sorensen, Jesus G. Berdeja, Michael Savona, Lynn Savoie, Suzanne Trudel, Nuchanan Areethamsirikul, T. J. Unger, Tami Rashal, Tim Hanke, Michael Kauffman, Sharon Shacham, Donna Reece
Journal: Blood
Blood (2018) 131 (8): 855–863.
https://doi.org/10.1182/blood-2017-08-797886
Published: 2018
Includes: Supplemental data
Journal Articles

Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma

Clinical Trials & Observations
John Kuruvilla, Michael Savona, Rachid Baz, Paul Morten Mau-Sorensen, Nashat Gabrail, Ramiro Garzon, Richard Stone, Michael Wang, Lynn Savoie, Peter Martin, Ian Flinn, Meagan Jacoby, Thaddeus J. Unger, Jean-Richard Saint-Martin, Tami Rashal, Sharon Friedlander, Robert Carlson, Michael Kauffman, Sharon Shacham, Martin Gutierrez
Journal: Blood
Blood (2017) 129 (24): 3175–3183.
https://doi.org/10.1182/blood-2016-11-750174
Published: 2017
Includes: Supplemental data
Journal Articles

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia

Clinical Trials & Observations
Ramiro Garzon, Michael Savona, Rachid Baz, Michael Andreeff, Nashat Gabrail, Martin Gutierrez, Lynn Savoie, Paul Morten Mau-Sorensen, Nina Wagner-Johnston, Karen Yee, Thaddeus J. Unger, Jean-Richard Saint-Martin, Robert Carlson, Tami Rashal, Trinayan Kashyap, Boris Klebanov, Sharon Shacham, Michael Kauffman, Richard Stone
Journal: Blood
Blood (2017) 129 (24): 3165–3174.
https://doi.org/10.1182/blood-2016-11-750158
Published: 2017
Includes: Supplemental data
Journal Articles

Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

Christine Chen, MD, Ramiro Garzon, MD, Martin Gutierrez, Meagan A. Jacoby, MD PhD, Peter Brown, Ian Flinn, Richard M. Stone, MD, Mary Lynn Savoie, MD, Rachid Baz, Nashat Y. Gabrail, MD, Michael Wang, MD, Peter Martin, MD, David Siegel, MD PhD, Morten Mau-Sørensen, Michael Andreef, Tracey Marshall, Jean-Richard Saint-Martin, Robert Carlson, Sharon Shacham, Michael Kauffman, John Kuruvilla, MD
Journal: Blood
Blood (2015) 126 (23): 258.
https://doi.org/10.1182/blood.V126.23.258.258
Published: 2015
Journal Articles

The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL)

John Kuruvilla, MD, John C. Byrd, MD, Joseph M Flynn, Ramiro Garzon, MD, Pierluigi Porcu, MD, Nina Wagner-Johnston, Mary Lynn Savoie, MD FRCPC, Richard M. Stone, MD, Eric D. Jacobsen, MD, Morten Mau-Sorensen, MD, Peter de Nully Brown, Rachid Baz, MD, Bijal Shal, MD, Ian Flinn, Nashat Gabrail, MD, Vishal Kukreti, MD, Rodger E. Tiedemann, MD PhD, Yosef Landesman, PhD, Boris Klebanov, M.A., MsC, Eran Shacham, PhD, Jean-Richard Saint-Martin, Tracey Marshall, John McCartney, PhD, Dilara McCauley, PhD, Robert Carlson, PhD, Sasha Norori, MSc, Michael R Savona, MD, Tami Rashal, MD, Mansoor R Mirza, MD, Michael Kauffman, MD PhD, Sharon Shacham, PhD MBA
Journal: Blood
Blood (2014) 124 (21): 396.
https://doi.org/10.1182/blood.V124.21.396.396
Published: 2014
Journal Articles

Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM)

Christine I. Chen, MD MD FRCPC, Martin Gutierrez, MD, David S. Siegel, MD PhD, Joshua R. Richter, MD, Nina Wagner-Johnston, Craig C Hofmeister, MD MPH, Jesus G. Berdeja, MD, Nashat Gabrail, MD, Rachid Baz, MD, Morten Mau-Sorensen, MD, Suzanne Trudel, MD MSC, FRCPC, Rodger E. Tiedemann, MD PhD, Vishal Kukreti, MD, Nuchanan Areethamsirikul, MD, Asfar Azmi, PhD, Trinayan Kashyap, MSc, Yosef Landesman, PhD, Tracey Marshall, John McCartney, PhD, Jean-Richard Saint-Martin, Sasha Norori, MSc, Michael R Savona, MD, Tami Rashal, MD, Robert Carlson, PhD, Mansoor R Mirza, MD, Sharon Shacham, PhDMBA, Michael Kauffman, MD PhD, Donna E Reece, MD FRCPC
Journal: Blood
Blood (2014) 124 (21): 4773.
https://doi.org/10.1182/blood.V124.21.4773.4773
Published: 2014
Journal Articles

Phase I Trial of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Advanced Acute Myelogenous Leukemia (AML)

Michael Savona, MD, Ramiro Garzon, MD, Peter de Nully Brown, MD, Karen Yee, MD, Jeffrey E. Lancet, MD, Martin Gutierrez, MD, Nashat Gabrail, MD, Morten Mau-Sorensen, MD, Rachid Baz, MD, John C. Byrd, MD, John Kuruvilla, MD, David S. Siegel, MD, PhD, Sharon Shacham, PhD, MBA, Tami Rashal, MD, Cindy YF Yau, MSc, CCRP, Dilara McCauley, PhD, Jean-Richard Saint-Martin, John McCartney, PhD, Yosef Landesman, PhD, Boris Klebanov, Greg Pond, PhD, Amit M. Oza, MBBS, MD, Michael Kauffman, MD, PhD, Mansoor R Mirza, MD, Richard M. Stone, MD
Journal: Blood
Blood (2013) 122 (21): 1440.
https://doi.org/10.1182/blood.V122.21.1440.1440
Published: 2013
Journal Articles

Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom’s Macroglobulinemia (WM)

Christine I. Chen, MD, Martin Gutierrez, MD, Peter de Nully Brown, Nashat Gabrail, MD, Rachid Baz, MD, Donna E. Reece, MD, Michael Savona, MD, Suzanne Trudel, MD, MSC, FRCPC, David S. Siegel, MD, PhD, Morten Mau-Sorensen, MD, John Kuruvilla, MD, FRCPC, John C. Byrd, MD, Sharon Shacham, PhD, MBA, Tami Rashal, MD, Cindy YF Yau, MSc, CCRP, Dilara McCauley, PhD, Jean-Richard Saint-Martin, John McCartney, PhD, Yosef Landesman, PhD, Boris Klebanov, Greg Pond, PhD, Amit M. Oza, MBBS, MD, Michael Kauffman, MD, PhD, Mansoor R Mirza, MD
Journal: Blood
Blood (2013) 122 (21): 1942.
https://doi.org/10.1182/blood.V122.21.1942.1942
Published: 2013
Journal Articles

Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Ofa First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

John Kuruvilla, MD, Martin Gutierrez, MD, Bijal D. Shah, MD, Nashat Y. Gabrail, MD, Peter de Nully Brown, Richard M. Stone, MD, Ramiro Garzon, MD, Michael Savona, MD, David S. Siegel, MD, PhD, Rachid Baz, MD, Morten Mau-Sorensen, MD, Matthew S. Davids, MD, John C. Byrd, MD, Sharon Shacham, PhD, MBA, Tami Rashal, MD, Cindy YF Yau, Dilara McCauley, PhD, Jean-Richard Saint-Martin, John McCartney, PhD, Yosef Landesman, PhD, Boris Klebanov, Greg Pond, PhD, Amit M. Oza, MBBS, MD, Michael Kauffman, MD, PhD, Mansoor R Mirza
Journal: Blood
Blood (2013) 122 (21): 90.
https://doi.org/10.1182/blood.V122.21.90.90
Published: 2013